Operating income changed across a sign change
Operating income changed +604.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$1.5M→$7.6M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →PHR financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue increased 10.4%
Revenue changed +10.4% from the comparable as-filed period.
$117.3M→$129.5M3 prior comparisons
Capex / revenue moved 113 bp lower
Capex / revenue changed -113 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
1.51%→0.38%3 prior comparisons
Stock-based compensation decreased 26.8%
Stock-based compensation changed -26.8% from the comparable as-filed period.
$16.2M→$11.9M3 prior comparisons
Debt decreased 12.2%
Debt changed -12.2% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
$1.3M→$1.1M8 prior comparisons
Research & development decreased 5.8%
Research & development changed -5.8% from the comparable as-filed period.
$29.3M→$27.6M3 prior comparisons
Revenue increased 12.9%
Revenue changed +12.9% from the comparable as-filed period.
$115.9M→$130.9M3 prior comparisons
Operating income changed across a sign change
Operating income changed +305.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$3.3M→$6.7M3 prior comparisons
Cash & equivalents decreased 15.9%
Cash & equivalents changed -15.9% from the comparable as-filed period.
$90.9M→$76.4M2 prior comparisons
Net income changed across a sign change
Net income changed +175.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$3.9M→$3.0M2 prior comparisons
Research & development decreased 11.0%
Research & development changed -11.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$31.8M→$28.3M3 prior comparisons
Capital expenditure increased 23.0%
Capital expenditure changed +23.0% from the comparable as-filed period.
$3.5M→$4.3M3 prior comparisons
Stock-based compensation decreased 21.3%
Stock-based compensation changed -21.3% from the comparable as-filed period.
$17.2M→$13.6M3 prior comparisons
Capex / revenue moved 27 bp higher
Capex / revenue changed +27 basis points from the comparable as-filed period.
3.02%→3.29%3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.